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Background: Cranberry is one of the most commonly used herbs during pregnancy. The herb has been used
traditionally against urinary tract infections. No studies are found that specifically address the risk of malformations
after use of cranberry during pregnancy. The aim of the study was to investigate the safety of cranberry use during
pregnancy, including any effects on congenital malformations and selected pregnancy outcomes.
Methods: The study is based on data from The Norwegian Mother and Child Cohort Study including more than
100,000 pregnancies from 1999 to 2008. Information on use of cranberry and socio-demographic factors was
retrieved from three self-administered questionnaires completed by the women in pregnancy weeks 17 and 30, and
6 months after birth. Information on pregnancy outcomes was retrieved from the Medical Birth Registry of Norway.
Results: Among the 68,522 women in the study, 919 (1.3%) women had used cranberry while pregnant. We did not
detect any increased risk of congenital malformations after use of cranberry. Furthermore, the use of cranberry was also
not associated with increased risk for stillbirth/neonatal death, low birth weight, small for gestational age, preterm birth,
low Apgar score (<7), neonatal infections or maternal vaginal bleeding in early pregnancy. Although an association was
found between use of cranberry in late pregnancy and vaginal bleeding after pregnancy week 17, further sub-analyses
of more severe bleeding outcomes did not support a significant risk.
Conclusions: The findings of this study, revealing no increased risk of malformations nor any of the following
pregnancy outcomes; stillbirth/neonatal death, preterm delivery, low birth weight, small for gestational age, low Apgar
score and neonatal infections are reassuring. However, maternal vaginal bleeding should be investigated further before
any firm conclusion can be drawn. Treatment guidelines on asymptomatic bacteriuria in pregnancy recommend
antimicrobial therapy as the first line treatment. According to our data and the outcomes studied, cranberry does not
appear to be a harmful adjunctive self-treatment.
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Pregnancy outcomeBackground
Cranberry (Vaccinium macrocarpon Aiton), also known as
American Cranberry, is a fruit native to North America,
and has been used traditionally against urinary tract infec-
tions (UTIs) [1]. It is included in the United States
Pharmacopeia as Cranberry Liquid Preparation [2], and
is usually administered as cranberry juice cocktail or as* Correspondence: kristine.heitmann@igs.uib.no
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reproduction in any medium, provided the orcapsules. Cranberry is one of the most commonly used
herbs during pregnancy, and five studies report prevalence
rates of over 5% [3-7].
UTIs are the most common bacterial infections in preg-
nancy and may be classified as asymptomatic or symptom-
atic [8]. The incidence of asymptomatic bacteriuria (ASB)
in pregnancy has been reported to be 2–14%, similar to
the incidence in non-pregnant women [9]. However, preg-
nant women have an increased risk of progression of ASB
into pyelonephritis compared to non-pregnant women,
20–40% vs. 1–2%, respectively [9]. The risk of ascendingral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the mechanical effects of the enlarged uterus and in-
creased levels of progesterone [10]. Symptomatic urinary
tract infections are classified as lower tract (cystitis), and
upper tract infections (pyelonephritis), which occur in 1–
4% and 0.5–2% of all pregnancies, respectively [8,9].
The consequences of UTI on pregnancy outcomes are
well documented. Bacteriuria has been associated with
an increased risk of preterm birth, intrauterine growth
restriction and low birth weight in several studies
[11-14]. Pyelonephritis is the second most common, and
a serious, medical problem in pregnancy [10]. It has
been associated with different perinatal complications
and adverse pregnancy outcomes including bacteraemia,
septic shock, respiratory insufficiency, anaemia, renal
disease, hypertension, preterm delivery and low birth
weight [8,12,13,15,16]. Use of antibiotics against ASB
has been shown to reduce the risk of low birth weight
[11,17]. Thus, guidelines on UTI in pregnancy clearly
state that UTI should be treated with antibiotics [18,19].
Cranberries’ mechanism of action has not been fully elu-
cidated, though it is thought to be attributed to two com-
ponents, proanthocyanidins and fructose [20]. These two
components have been shown to inhibit adherence of bac-
teria to the cells lining the wall of the bladder [21-23], but
do not seem to have the ability to release bacteria already
adhered to those cells [24]. According to a Cochrane re-
view, there is no scientific evidence to support the use of
cranberry for treating UTIs [25]. Until recently, there was
some evidence supporting the use of cranberry in preven-
tion of recurrent UTIs, especially in women [26], but the
recently updated Cochrane review states that, currently,
there is insufficient evidence to recommend cranberry for
prevention of recurrent UTIs [27]. However, pooled re-
sults from two studies comparing a cranberry product
with antibiotics showed no significant difference between
groups in terms of risk of recurrent UTI [27].
The widespread use in pregnancy is in contrast to the
sparse body of evidence on both safety and effectiveness
of cranberry use during pregnancy against UTIs. One
study investigating the efficacy of cranberry for the pre-
vention of ASB in pregnancy is found [28]. This was a
three-arm study comparing a single daily dose (240 ml)
or two/three daily doses (480 ml to 720 ml) of cranberry
juice cocktail with a placebo beverage. Though not
significant, the authors found a trend of fewer UTIs in
the group ingesting two/three doses of cranberry juice
cocktail compared to the group ingesting a single daily
dose and the placebo group (6.9% vs. 11.1% and 10.4%,
respectively). This study did not detect any differences
between the groups with regards to obstetrical or neo-
natal outcomes such as preterm delivery, route of deliv-
ery, birth weight, Apgar score or admission to neonatal
intensive care unit. No studies are found that specificallyaddress the risk of malformations after use of cranberry
during pregnancy. Though textbooks refer to the long
history of safe use and no known negative reports re-
garding the use of cranberry during pregnancy, it is also
stated that there is a need for evidence based documen-
tation [29-31]. No case reports of negative pregnancy
outcome are discovered. However, since cranberry prob-
ably is ineffective in treating UTIs in pregnancy, it is
possible that using cranberry as replacement for antibi-
otics will have negative consequences on pregnancy out-
come due to the untreated underlying infection.
Previous literature indicates a possible interaction be-
tween cranberry and warfarin, and different mechanisms
have been postulated [20,32,33]. Although elevations of
the international normalized ratio (INR) after consump-
tion of cranberry have been described in a number of case
reports, results from clinical trials have been conflicting
[32,34]. It is unknown whether ingestion of cranberry may
increase the risk of bleeding in other vulnerable patient
groups, e.g. pregnant women.
The primary aim for this study was to investigate
whether use of cranberry during pregnancy was associ-
ated with an increased risk of malformations. The sec-
ondary aim was to examine whether use of cranberry
during pregnancy was associated with selected preg-
nancy outcomes such as stillbirth/neonatal death, low
birth weight, preterm birth, low Apgar score, neonatal
infections and maternal vaginal bleeding.
Methods
The data used in this study was provided by the Norwegian
Mother and Child Cohort Study (MoBa) and the records
from the Medical Birth Registry of Norway (MBRN).
Access to MoBa was granted by the MoBa steering com-
mittee at the National Institute of Public Health according
to regulations for MoBa-substudy projects. MoBa is a
population-based prospective cohort study initiated by and
maintained at the Norwegian Institute of Public Health in-
cluding more than 100,000 pregnancies from 1999 to 2008
[35]. Pregnant women received a postal invitation including
an informed consent form and the first questionnaire
together with an appointment for a routine ultrasound
examination during pregnancy week 17–18 [36]. The re-
cruitment originated in the county of Hordaland and ex-
panded gradually to become nationwide in 2005, with 50
of 52 hospitals in Norway participating. The participation
rate was 43.8% according to an assessment of MoBa in
June 2009 [36]. Three self-administered questionnaires
from MoBa were used to retrieve information [37-39].
The first and second questionnaires were completed dur-
ing pregnancy weeks 13–17 and 30 [37,38], respectively,
and the third was completed when the child was 6 months
old [39]. The questionnaires provide information on
socio-demographic characteristics, outcomes of previous
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habits, drug exposure, and other exposures, e.g. use of
herbal products. Among respondents who participated,
the response rate was 95% for the first questionnaire, 92%
for the second questionnaire, and 87% for the third ques-
tionnaire [36].
The cohort database is linked to the MBRN via the
woman’s 11 digit personal identification number, which is
assigned to individuals registered in the National Popula-
tion Register as residents of Norway. Since the establish-
ment of MBRN in 1967 it has been compulsory to notify
the register of every birth or late abortion, including live
birth, stillbirth and induced abortions after gestational
week 12 (after week 16 up to 2002), occurring in Norway
[40,41]. The registry contains information on pregnancy,
delivery, and the health of the neonate [41].
MoBa was approved by the Regional Committee for
Ethics in Medical Research, Region South, and the Nor-
wegian Data Inspectorate.
Study population
The current study uses version 4 of the MoBa quality as-
sured data files made available for research. This file
includes 72,934 women who delivered between 1999 and
2006. To be included in the current study, the women had
to have a record in MBRN and to have answered the first
questionnaire (n = 69,930). Women who gave birth to
multiples (n = 1,291) or who gave birth to infants with
chromosomal malformations (n = 121) were excluded.
This resulted in a study population of 68,522 pregnant
women and their newborn infants, corresponding to
94.0% of the original data file. Among the included
women, 92.5% had answered the second questionnaire
and 87.3% had answered the third questionnaire.
Exposure variable
Information on cranberry use was retrieved from the three
MoBa questionnaires [37-39]. In each questionnaire, it
was asked if the women had experienced specified com-
plaints, including UTI. The women could specify several
products used and exposure windows for each separately,
when the complaint was experienced and when the prod-
ucts were used; in the first questionnaire: 6 months before
pregnancy, gestational weeks 0–4, 5–8, 9–12 and 13+
(until completion of the first questionnaire); in the second
questionnaire: gestational weeks 13–16, 17–20, 21–24,
25–28, 29+ (until completion of the second question-
naire); and in the third questionnaire: last part of preg-
nancy, 0–3 months after birth and 4–6 months after birth.
In addition, the questionnaires included a question about
use of all vitamins and dietary supplements, including al-
ternative/herbal remedies, in which the women were
asked to give complete names of the products. In this
question, it was not possible to specify either timing of useor indication. All medicine text fields and text fields for
dietary supplements/herbal remedies in the three ques-
tionnaires were systematically reviewed for herbal prod-
ucts by the research team (see also acknowledgement).
Whenever a herbal product was identified, the herbal in-
gredient(s) was systematically coded according to a pre-
determined herbal classification list. This classification
system had been developed by the research team and in-
cluded the common name of the herb and a seven charac-
ter specific code as a means to standardize the coding in
the questionnaire database. Cranberry was defined as any
herbal coded with the assigned herbal code 59.
Exposure was classified as use of cranberry during
pregnancy (total), use of cranberry during early preg-
nancy (before pregnancy week 17) and use of cranberry
during late pregnancy (at and after pregnancy week 17).
Sub-analyses stratifying on timing of use and co-
medication with antibiotics were performed.
Outcome variables
Information on outcome variables was abstracted from
the MBRN. Diagnoses were based on the International
Classification of Diseases, 10th Revision (ICD-10) [42].
Malformations were classified as all malformations,
major malformations and cardiovascular malformations.
Malformations (all malformations) were defined as any
birth defect registered in the MBRN [43]. Malformations
were classified as major by the MBRN using the Inter-
national Clearinghouse of Birth Defects definition [43].
Cardiovascular malformations were defined as all mal-
formations classified with ICD-10 code Q20-26 [43].
Other outcome variables included in the study were
stillbirth/neonatal death, low birth weight (<2500 g),
small for gestational age (SGA) (under the 10th percent-
ile for the gestational age), preterm birth (<37 weeks
gestational age), Apgar score <7 at 5 minutes after birth
and neonatal infections. Stillbirth was defined as the
death of a foetus with a gestational age of ≥22 weeks or
with a birth weight of ≥425 g. Neonatal death was de-
fined as a live born infant that died within the first
28 days after birth. Neonatal infections were defined as
all diagnoses classified with ICD-10 P35-39. The out-
comes were not mutually exclusive.
The MoBa study provided information on the different
variables related to maternal vaginal bleeding: vaginal
bleeding before pregnancy week 17, vaginal bleeding at
week 17 and after, hospitalization due to vaginal bleed-
ing before week 17, hospitalization due to vaginal bleed-
ing at week 17 and after, vaginal bleeding more than
spotting after week 17.
Other variables
The following potential confounders were explored in
relation to cranberry use and the different outcome
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≥35 years); parity [0 previous live births, ≥1 previous live
birth(s)], education (primary, secondary, tertiary-short,
tertiary-long); marital status (married or cohabitating,
other); pre-pregnancy body mass index (BMI) under-
weight (<18.5 kg/m2), normal weight (18.5 – 24.99 kg/m2),
overweight (25.0 – 29.99 kg/m2), obese (≥ 30 kg/m2);
physical activity (never, less than once a week, 1–2 times
weekly, 3 or more times weekly); maternal mother tongue
(Norwegian, other); smoking at the end of pregnancy (no,
sometimes, daily); any folic acid use (no; yes, before or
during; yes, before and during), and year of delivery
(1999–2002, 2003–2006).
Maternal UTI was classified as UTI during early preg-
nancy (before week 17), UTI during late pregnancy (at
week 17 and after), and UTI during pregnancy at any
time point (total). In addition, sick leave, previous mis-
carriages or stillbirths, use of antibiotics against UTI and
maternal vaginal infections including vaginal thrush, va-
ginal catarrh/ unusual discharge and/or chlamydia, were
variables that were included. These variables were di-
chotomized yes/no.
Statistical analyses
Pearson’s chi-square test was used to explore potential as-
sociations between maternal characteristics listed in Table 1
and cranberry use. In cases where the expected value in
any of the cells of a contingency table was below 5, Fisher’s
exact test was applied. P-values of <0.05 were considered
significant. To estimate the risk of malformations and se-
lected pregnancy outcomes, crude and adjusted odds ratios
(ORs) were obtained by performing univariate and multi-
variate generalized estimating equations. ORs are presented
with 95% confidence intervals (CIs). The generalized esti-
mating equation with the binary logistic model was used to
correct for possible correlations between pregnancies if the
women had participated with more than one pregnancy. In
total, 6,972 (10.2%) women had participated with more
than one pregnancy. Of note, we also performed univariate
and multivariate logistic regression analyses and compared
the effect estimates obtained to those obtained by general-
ized estimating equations. However, the two effect esti-
mates differed only slightly, hence the ORs and CIs
calculated by using generalized estimating equations are
presented in the text and tables. The variables listed in
Table 1 were considered potential confounders. Statistically
or clinically significant variables were explored for each
pregnancy outcome. The selection of variables to be in-
cluded in the potential confounder sets was based on the-
oretically potential influences, as well as the results from
exploratory data analysis. Possible high inter-correlations
among the independent variables were checked for, using
multiple regression analysis and ensuring that the tolerance
values for collinearity statistics were adequate (>0.1).We also performed generalized estimating equations
analyses stratifying on antibiotic treatment to further in-
vestigate the risk of the selected adverse pregnancy out-
comes among the women who had used cranberry and
who reported to have had at least one episode of UTI
during pregnancy. The confounder sets used when esti-
mating the risks for the adverse pregnancy outcomes
were identical to the previously described, with the ex-
clusion of UTI.
Given the 919 cases of exposures to cranberry during
pregnancy, and the 566 exposures to cranberry during
early pregnancy, the study had ≥80% statistical power to
rule out a doubling or more of the risk of the following
outcomes: malformations overall, serious malformations,
low birth weight, low Apgar score, preterm birth and
neonatal infections, and a tripling or more of the risk of
the following outcomes: cardiac malformations and still-
birth/neonatal death.
The Statistical Package for Social Sciences version 20.0
(IBM SPSS Statistics 20) for Windows (SPSS, Chicago,
IL, USA) was used to perform all the statistical analyses.
Results
A total of 68,522 pregnancies were included in the study,
of which 68,198 (99.5%) resulted in a live birth, 219
(0.3%) in a stillbirth, 104 (0.2%) in a neonatal death, and
24 (0.0004%) in an induced abortion after week 12. The
overall rate of malformations was 4.7%. The mean birth
weight was 3605 gram (standard deviation (SD) 590 g)
and the median gestational age was 40 weeks among the
live born neonates.
In total, 919 (1.3%) women reported use of cranberry
during pregnancy. Among the women who had used
cranberry, 121 (13.2%) women had used cranberry dur-
ing the first trimester, and 566 (61.6%) women reported
use during early pregnancy (in the first questionnaire).
The women who had used cranberry were more likely to
be primiparous, to have a college education (tertiary
education-short), to have Norwegian as their maternal
mother tongue and to have given birth during the time
period 2003–2006, compared to the women who did not
use cranberry (Table 1). In addition, women who had
used cranberry were less likely to be daily smokers and
non-users of folic acid.
The women who had used cranberry were more likely to
have experienced UTI during pregnancy compared to
women who did not use cranberry. In addition, a signifi-
cantly higher proportion of the women who had used cran-
berry had experienced vaginal infections including vaginal
thrush, vaginal catarrh/unusual discharge and chlamydia.
Among the women who had used cranberry, 554
(60.3% of 919) had experienced UTI at any time point
during pregnancy. In total, UTI was experienced by
7,311 (10.7% of 68,522) of the women, of which 1,557
Table 1 Characteristics of women according to cranberry use, n = 68,522a
Total No cranberry use
during pregnancy
Use of cranberry
during pregnancy
No exposure to
cranberry and UTI
Exposed to cranberry,
UTI and antibiotics
against UTI during
pregnancy
Exposed to cranberry,
UTI and no antibiotics
against UTI during
pregnancy
No. (%) No. (%) No. (%) N (%) N (%) N (%)
68,522 (100.0) 67,603 (98.7) 919 (1.3) P-valueb 60,846 (88.8) 254 (0.4) 300 (0.4) P-valueb
Age (years)
≤ 24 8,034 (11.7) 7,930 (11.7) 104 (11.3)
0.621
6,893 (11.3) 28 (11.0) 32 (10.7)
0.952
25–29 23,050 (33.6) 22,725 (33.6) 325 (35.4) 20,442 (33.6) 88 (34.6) 106 (35.3)
30–34 26,157 (38.2) 25,822 (38.2) 335 (36.5) 23,454 (38.5) 92 (36.2) 110 (36.7)
≥ 35 11,281 (16.5) 11,126 (16.5) 155 (16.9) 10,057 (16.5) 46 (18.1) 52 (17.3)
Parity
0 previous live births 29,778 (43.5) 29,272 (43.3) 506 (55.1)
<0.001
26,090 (42.9) 152 (59.8) 147 (49.0)
<0.001
≥1 38,738 (56.5) 38,325 (56.7) 413 (44.9) 34,750 (57.1) 102 (40.2) 153 (51.0)
Educationc
Primary 6,123 (8.9) 6,060 (9.0) 63 (6.9)
<0.001
5,287 (8.7) 14 (5.5) 26 (8.7)
0.032
Secondary 20,519 (29.9) 20,261 (30.0) 258 (28.1) 18,069 (29.7) 64 (25.2) 97 (32.3)
Tertiary-short 27,204 (39.7) 26,777 (39.6) 427 (46.5) 24,264 (39.9) 128 (50.4) 120 (40.0)
Tertiary-long 13,112 (19.1) 12,956 (19.2) 156 (17.0) 11,817 (19.4) 45 (17.7) 50 (16.7)
Marital status
Married/cohabitating 65,765 (96.0) 64,878 (96.0) 887 (96.5)
0.320
58,536 (96.2) 246 (96.7) 288 (96.0)
0.834
Other 2,427 (3.5) 2,400 (3.6) 27 (2.9) 2,017 (3.3) 7 (2.8) 11 (3.7)
Pre-pregnancy BMId
Underweight 2,055 (3.0) 2,022 (3.0) 33 (3.6)
0.195
1,799 (3.0) 7 (2.8) 15 (5.0)
0.218
Normal weight 43,058 (62.8) 42,446 (62.8) 612 (66.6) 38,377 (63.1) 167 (65.7) 178 (59.3)
Overweight 14,736 (21.5) 14,558 (21.5) 178 (19.4) 13,052 (21.5) 50 (19.7) 67 (22.3)
Obese 6,538 (9.5) 6,452 (9.5) 86 (9.4) 5,701 (9.4) 26 (10.2) 37 (12.3)
Physical activity
Never 10,293 (15.0) 10,164 (15.0) 129 (14.0)
0.417
9,080 (14.9) 31 (12.2) 45 (15.0)
0.538
Less than once a week 16,218 (23.7) 16,000 (23.7) 218 (23.7) 14,423 (23.7) 57 (22.4) 65 (21.7)
1-2 times weekly 25,747 (37.6) 25,369 (37.5) 378 (41.1) 22,931 (37.7) 111 (43.7) 124 (41.3)
3 times or more weekly 11,121 (7.5) 10,969 (16.2) 152 (16.5) 9,871 (16.2) 42 (16.5) 50 (16.7)
Missing 5,143 (7.5) 5,101 (7.5) 42 (4.6) 4,541 (7.5) 13 (5.1) 16 (5.3)
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Table 1 Characteristics of women according to cranberry use, n = 68,522a (Continued)
Maternal mother tongue
Norwegian 64,812 (94.6) 63,929 (94.6) 883 (96.1)
0.043
57,511 (94.5) 248 (97.6) 287 (95.7)
0.064
Other 3,710 (5.4) 3,674 (5.4) 36 (3.9) 3,335 (5.5) 6 (2.4) 13 (4.3)
Smoking at the end of pregnancy
No 53,198 (77.6) 52,468 (77.6) 730 (79.4)
0.024
47,283 (77.7) 202 (79.5) 236 (78.7)
0.623
Sometimes 472 (0.7) 462 (0.7) 10 (1.1) 409 (0.7) 0 (0.0) 3 (1.0)
Daily 3,524 (5.1) 3,492 (5.2) 32 (3.5) 3041 (5.0) 10 (3.9) 14 (4.7)
Missing 11,328 (16.5) 11,181 (16.5) 147 (16.0) 10,113 (16.6) 42 (16.5) 47 (15.7)
Any folic acid usee
No 32,098 (46.8) 31,715 (46.9) 383 (41.7)
0.007
28,356 (46.6) 108 (42.5) 123 (41.0)
0.044Yes, before or during 21,735 (31.7) 21,417 (31.7) 318 (34.6) 19,294 (31.7) 96 (37.8) 97 (32.3)
Yes, before and during 14,689 (21.4) 14,471 (21.4) 218 (23.7) 13,196 (21.7) 50 (19.7) 80 (26.7)
Year of delivery
1999-2002 13,640 (19.9) 13,482 (19.9) 158 (17.2)
0.038
11,985 (19.7) 43 (16.9) 69 (23.0)
0.1922003-2006 54,882 (80.1) 54,121 (80.1) 761 (82.8) 48,861 (80.3) 211 (83.1) 231 (77.0)
Sick leave
Yes 43,300 (63.2) 42,693 (63.2) 607 (66.1) 0.070 38,147 (62.7) 172 (67.7) 198 (66.0) 0.128
Previous miscarriages/stillbirths
Yes 14,975 (21.9) 14,786 (21.9) 189 (20.6) 0.341 13,279 (21.8) 49 (19.3) 57 (19.0) 0.311
Vaginal infectionsf
Yes 21,924 (32.0) 21,514 (31.8) 410 (44.6) <0.001 18,642 (30.6) 125 (49.2) 145 (48.3) <0.001
Urinary tract infection (UTI)
UTI during early pregnancyg 4,624 (6.7) 4,222 (6.2) 402 (43.7) <0.001 - - -
UTI during late pregnancyh 3,766 (5.5) 3,462 (5.1) 304 (33.1) <0.001 - - -
UTI during pregnancy at any time point 7,311 (10.7) 6,757 (10.0) 554 (60.3) <0.001 - - -
aNumbers may not add up to 68,522 due to missing values.
bP-values obtained by Pearson’s chi-square test or Fischer’s exact test when less than 5 in one or more of the cells. Significant findings are in bold.
cPrimary: <10 years of education (the Norwegian compulsory primary + secondary school), secondary: 10–12 years (high school/upper secondary or vocational school), tertiary-short: college education, tertiary-long:
university education.
dBody mass index (BMI) is the weight in kilograms divided by the square of the height in meters: underweight: <18.5 kg/m2, normal weight: 18.5–24.9 kg/m2; overweight: 25.0–29.9 kg/m2, obese ≥30 kg/m2.
eFolic acid use is reported from the 4 weeks prior to pregnancy to 3 months of gestation.
fIncluding vaginal thrush, vaginal catarrh/unusual discharge and/or chlamydia.
gEarly pregnancy is defined as before pregnancy week 17.
hLate pregnancy is defined as during or after pregnancy week 17.
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http://www.biomedcentral.com/1472-6882/13/345(21.3% of 7,311) women experienced more than one epi-
sode of UTI. Among the women who experienced UTI
during pregnancy, 4,085 (55.9% of 7,311) reported using
antibiotics against UTI compared to the 554 (7.6% of
7,311) women who reported use of cranberry. Further-
more, 300 women reported using cranberry and experi-
encing a UTI during pregnancy without the concomitant
use of antibiotics.
Use of cranberry during early pregnancy did not in-
crease the risk of vaginal bleeding before pregnancy week
17 (21.7% for users vs. 19.3% for non-users, p = 0.15).
Additionally, use of cranberry during the first trimester
was not associated with hospitalization due to vaginal
bleeding (0.00% vs. 0.20%, p = 0.65). There was a higher
percentage of bleeding after week 17 following ingestion
of cranberry during the second and/or third trimester
(9.7% vs. 5.8%, p < 0.001). However, no associations were
found between use of cranberry during the second and/or
third trimester and more severe bleeding outcomes such
as vaginal bleeding more than spotting after pregnancy
week 17 (3.1% vs. 2.1%, p = 0.08), or hospitalization due to
vaginal bleeding after pregnancy week 12 (0.8% vs. 0.7%,
p = 0.60). Furthermore, when adjusting for maternal age,
parity, pre-pregnancy BMI, maternal smoking, maternal
folic acid use, UTI, previous miscarriages or stillbirths,
and physical activity, no associations were found between
use of cranberry during the second and/or third trimester
and bleeding after week 17 (adjusted OR 1.3, 95% CI 1.0–
1.8, p =0.08) or vaginal bleeding more than spotting after
week 17 (adjusted OR 1.2, 95% CI 0.8–2.1, p = 0.40).
No increased risk of overall malformations or major mal-
formations was found after exposure to cranberry during
early pregnancy (Table 2). There were no cases of cardiac
malformations among the women who used cranberry dur-
ing early pregnancy. Among the women who had used
cranberry during the first trimester only, there were 11
(9.1% of 121) cases of malformations in total, of which five
(4.1% of 121) were classified as major. However, sub-
analyses with first trimester exposures only revealed no in-
creased risk of overall malformations (adjusted OR 1.6,
95% CI 0.8–3.2) or major malformations (adjusted OR 1.3,
95% CI 0.5–3.6). The 11 cases of infants born with malfor-
mations after exposure to cranberry in the first trimesterTable 2 Association between malformations and exposure to
No exposure to cranberry (n = 67
Outcome Total (%) No. (%) Crude OR Adjuste
Malformations, all 3,201 (4.7) 3,145 (4.7) Ref. Re
Major malformations 1,777 (2.6) 1,753 (2.6) Ref. Re
Abbreviations: CI confidence interval, OR odds ratio, Ref. reference category.
*Odds ratios (ORs) resulting from Generalized estimating equations analyses are pre
aEarly pregnancy is defined as before pregnancy week 17.
Malformations were defined according to the definitions of the MBRN and Internati
Adjusted for maternal age, parity, pre-pregnancy BMI, level of education, maternal s
tongue and year of delivery.were scrutinized (data not shown). No specific pattern of
malformations was revealed. The five cases of serious mal-
formations were two cases of hypospadias, two cases of
macrocephaly and one case of congenital deformity of the
sternocleidomastoid muscle. The other cases which were
not classified as serious malformations were four cases of
congenital dislocation and other deformities of the hip (3
cases) and feet (1 case), one case of ankyloglossia and one
case of undescended testicle.
Use of cranberry during pregnancy did not seem to in-
crease the risk of any of the selected negative pregnancy
outcomes: stillbirth/neonatal death, low birth weight,
small for gestational age, preterm birth, low Apgar score
(<7) or neonatal infections (Table 3). Sub-analyses stratify-
ing on timing of use were performed. The obtained ad-
justed ORs did not reveal any significant associations with
the selected pregnancy outcomes by isolating cranberry
exposure in early or late pregnancy (data not shown).
In stratified analyses according to use of antibiotics
against UTI (Table 4), adjusted ORs did not indicate any
increased risk of the investigated pregnancy outcomes
for the two groups of women: 1) women who had been
exposed to cranberry, UTI and antibiotics and 2) women
who had been exposed to cranberry and UTI, but not to
antibiotics. Crude results detected an increased risk for
SGA-infants among the women who had been exposed
to cranberry, UTI without use of antibiotics. However,
further sub-analyses with adjustment for potential con-
founding factors were performed with women exposed
to UTI without any treatment and women exposed to
UTI, antibiotics and no cranberry, revealing no in-
creased risk for having a SGA-infant (adjusted OR 1.0,
95% CI 0.9–1.2 and adjusted OR 1.0, 95% CI 0.9–1.2,
respectively).
Discussion
Our findings are reassuring, showing no increased risk
of congenital malformations, stillbirth/neonatal death,
preterm delivery, low birth weight, small for gestational
age, low Apgar score and neonatal infections. To the
best of our knowledge, this is the first study to investi-
gate the risk of malformations after use of cranberry
during pregnancy. These results are in agreement withcranberry during early pregnancy, n = 68,522*
,603) Exposed to cranberry during early pregnancya (n = 566)
d OR No. (%) Crude OR (95% CI) Adjusted OR (95% CI)
f. 33 (5.8) 1.3 (0.9–1.8) 1.1 (0.8–1.7)
f. 11 (1.9) 0.7 (0.4–1.4) 0.7 (0.4–1.3)
sented in the table.
onal Clearinghouse for Birth Defects.
moking, folic acid use, UTI, previous miscarriages or stillbirths, maternal mother
Table 3 Pregnancy outcome according to cranberry exposure, n = 68,522*
No exposure to cranberry (n = 67,603) Exposed to cranberry during pregnancy (n = 919)
Outcome Total (%) No. (%) Crude OR Adjusted OR No. (%) Crude OR (95% CI) Adjusted OR (95% CI)
Stillbirth/neonatal deatha 323 (0.5) 319 (0.5) Ref. Ref. 4 (0.4) 0.9 (0.3–2.5) 1.1 (0.4–2.8)g
Preterm birthb 3,535 (5.2) 3,497 (5.2) Ref. Ref. 38 (4.1) 1.0 (0.8–1.4) 1.0 (0.8–1.4)h
Low birth weightc 2,182 (3.2) 2,160 (3.2) Ref. Ref. 22 (2.4) 0.7 (0.5–1.1) 0.7 (0.4–1.0)g
Small for gestational aged 4,281 (6.2) 4,226 (6.3) Ref. Ref. 55 (6.0) 1.0 (0.7–1.3) 0.8 (0.6–1.1)i
Low Apgar scoree 898 (1.3) 887 (1.3) Ref. Ref. 11 (1.2) 1.2 (0.7–2.0) 1.0 (0.6–1.8)g
Neonatal infectionsf 870 (1.3) 856 (1.3) Ref. Ref. 14 (1.5) 1.2 (0.7–2.1) 1.1 (0.6–1.9)j
Abbreviations: CI confidence interval, OR odds ratio, Ref. reference category.
*Odds ratios (ORs) resulting from Generalized estimating equations analyses are presented in the table.
The outcomes were not mutually exclusive.
aIncludes infants who were stillborn with a gestational age of ≥22 weeks or birth weight of ≥425 g, or who died during the first 28 days of life.
bIncludes infants born at a gestational age of <37 weeks, which WHO defines as preterm.
cIncludes infants with a birth weight of <2500 g, which WHO defines as low birth weight.
dIncludes infants with a birth weight below the 10th percentile at the attained gestational age.
eIncludes infants who had an Apgar score of < 7 at 5 min after birth.
fIncludes infants who were diagnosed with ICD-10 P35-39.
gAdjusted for maternal age, parity, pre-pregnancy BMI, folic acid use, smoking, UTI, education, previous miscarriages/stillbirths, length of gestation, maternal
mother tongue and year of delivery.
hAdjusted for maternal age, parity, pre-pregnancy BMI, folic acid use, smoking, UTI, education, previous miscarriages/stillbirths, maternal mother tongue, year of
delivery and vaginal catarrh.
iAdjusted for maternal age, parity, pre-pregnancy BMI, folic acid use, smoking, UTI, education, previous miscarriages/stillbirths, maternal mother tongue and year
of delivery.
jAdjusted for maternal age, parity, pre-pregnancy BMI, folic acid use, smoking, UTI, education, previous miscarriages/stillbirths, length of gestation, maternal
mother tongue, year of delivery and vaginal infections.
Heitmann et al. BMC Complementary and Alternative Medicine 2013, 13:345 Page 8 of 12
http://www.biomedcentral.com/1472-6882/13/345the safety findings of a prior pilot study of the efficacy
for the prevention of ASB in pregnancy showing no dif-
ferences between the cranberry groups and the control
group with regard to obstetric or neonatal pregnancy
outcomes [28]. However, we did find an increased risk of
vaginal bleeding occurring after pregnancy week 17
among the women who used cranberry during late preg-
nancy. This association was no longer significant after
adjustment was made.
Previous studies have indicated an interaction between
cranberry and warfarin [20,32,33,44]. The mechanism of
the interaction remains elusive, and different mecha-
nisms are mentioned in the literature [32,33,44]. Cran-
berry contains significant amounts of salicylic acid, and
might increase the risk of bleeding through its capacity
to inhibit platelet aggregation [20,32,45]. On the con-
trary, others state that salicylic acid does not share the
antiplatelet effect of acetylsalicylic acid [44,46]. Another
biologically plausible mechanism of action has been pro-
posed by Abdul et al. who observed a non-significant
trend towards decreased activity of clotting factors when
cranberry was co-administered with warfarin [33]. How-
ever, the authors did not find any significant independ-
ent effect on the clotting system when cranberry was
administered alone during the pre-treatment period.
Consequently, a clear explanation of the findings with
regards to bleeding in this current study is difficult to
obtain, but it cannot be completely ruled out that use of
cranberry during pregnancy might increase the risk of
maternal vaginal bleeding. In the current study, thedoses and form of administration were unknown. Vagi-
nal bleeding was self-reported and included spotting in
addition to more severe bleeding incidents. We did not
find a statistically significant association between use of
cranberry during early pregnancy and maternal vaginal
bleeding, or between use of cranberry during late preg-
nancy and more severe bleeding outcomes such as vagi-
nal bleeding more than spotting after pregnancy week
17 and hospitalization due to vaginal bleeding after preg-
nancy week 12. These findings are reassuring. Neverthe-
less, a non-significant trend was seen between use of
cranberry during late pregnancy and vaginal bleeding
more than spotting after pregnancy week 17. Conse-
quently, maternal vaginal bleeding is something that
should be explored in later studies with respect to ad-
ministration form and dosage.
There was no increased risk of malformations in general,
major malformations or cardiac malformations among the
women who had used cranberry during early pregnancy.
However, there was an increase in the proportion of mal-
formations in general in the group of women who had
ingested cranberry during the first trimester. Reassuringly,
adjusted analyses showed no significantly increased risk
for either malformations in general or for major malfor-
mations. Furthermore, the malformations varied in nature
and did not reveal any clear pattern.
Of note, the women who used cranberry were more
likely to be primiparous, to have a college education,
and less likely to smoke daily. These findings are in
accordance with studies characterizing the users of
Table 4 Pregnancy outcome according to cranberry use, UTI and use of antibiotics, n = 68,522*
No exposure to cranberry and UTI
(n = 60,846)
Exposed to cranberry, UTI and antibiotics against
UTI during pregnancy (n = 254)
Exposed to cranberry, UTI and no antibiotics
against UTI during pregnancy (n = 300)
Outcome Total (%) No. (%) Crude OR Adjusted OR No. (%) Crude OR (95% CI) Adjusted OR (95% CI) No. (%) Crude OR (95% CI) Adjusted OR (95% CI)
Stillbirth/neonatal deatha 323 (0.5) 293 (0.5) Ref. Ref. 1 (0.4) 0.8 (0.1–5.8) 0.8 (0.1–6.2)g 3 (1.0) 2.1 (0.7–6.5) 2.2 (0.7–6.6)g
Preterm birthb 3,535 (5.2) 3,124 (5.2) Ref. Ref. 15 (6.0) 1.2 (0.7–2.0) 1.1 (0.6–1.9)h 19 (6.4) 1.2 (0.8–2.0) 1.2 (0.8–2.0)h
Low birth weightc 2,182 (3.2) 1,934 (3.2) Ref. Ref. 3 (1.2) 0.4 (0.1–1.1) 0.5 (0.2–1.5)g 7 (2.4) 0.7 (0.3–1.5) 0.5 (0.2–1.0)g
Small for gestational aged 4,281 (6.2) 3,784 (6.2) Ref. Ref. 11 (4.3) 0.7 (0.4–1.3) 0.6 (0.3–1.1)i 30 (10.0) 1.7 (1.1–2.4) 1.4 (0.9–2.1)i
Low Apgar scoree 898 (1.3) 792 (1.3) Ref. Ref. 5 (2.0) 1.5 (0.6–3.7) 1.5 (0.6–3.8)g 7 (2.3) 1.8 (0.9–3.8) 1.5 (0.7–3.4)g
Neonatal infectionsf 870 (1.3) 770 (1.3) Ref. Ref. 3 (1.2) 0.9 (0.3–2.9) 0.8 (0.3–2.7)j 7 (2.3) 1.9 (0.9–4.0) 1.8 (0.9–3.9)j
Abbreviations: CI confidence interval, OR odds ratio, Ref. reference category.
*Odds ratios (ORs) resulting from Generalized estimating equations analyses are presented in the table. Significant findings are in bold.
The outcomes were not mutually exclusive.
aIncludes infants who were stillborn with a gestational age of ≥22 weeks or birth weight of ≥425 g, or who died during the first 28 days of life.
bIncludes infants born at a gestational age of <37 weeks, which WHO defines as preterm.
cIncludes infants with a birth weight of <2500 g, which WHO defines as low birth weight.
dIncludes infants with a birth weight below the 10th percentile at the attained gestational age.
eIncludes infants who had an Apgar score of < 7 at 5 min after birth.
fIncludes infants who were diagnosed with ICD-10 P35-39.
gAdjusted for maternal age, parity, pre-pregnancy BMI, folic acid use, smoking, education, previous miscarriages/stillbirths, length of gestation, maternal mother tongue and year of delivery.
hAdjusted for maternal age, parity, pre-pregnancy BMI, folic acid use, smoking, education, previous miscarriages/stillbirths, maternal mother tongue, year of delivery and vaginal infections.
iAdjusted for maternal age, parity, pre-pregnancy BMI, folic acid use, smoking, education, previous miscarriages/stillbirths, maternal mother tongue and year of delivery.
jAdjusted for maternal age, parity, pre-pregnancy BMI, folic acid use, smoking, education, previous miscarriages/stillbirths, length of gestation, maternal mother tongue, year of delivery, vaginal infections.
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[3,6,47,48]. Additionally, the association between use of
cranberry and use of folic acid is in agreement with prior
results showing an association between the use of herbs
during pregnancy and use of multivitamins [49]. More
women who used cranberry gave birth during the period
2003 to 2006 compared to the period 1999 to 2002. This
observation mirrors the frequent use of CAM seen dur-
ing the recent years in the general population in many
Western countries [50-52].
The proportion of women who report treatment with
antibiotics in relation to UTI (55.9%) is worryingly low.
Pregnant women are previously found to overestimate
the risk of medicines [53,54], which may explain this
finding. Furthermore, a considerable proportion of the
women who used cranberry reported to have experi-
enced a UTI during pregnancy, and many of these
women did not report use of antibiotics against this con-
dition. Of note, this group had ORs above 1 for five out
of six outcomes shown in Table 4, which may be ex-
plained by improper treatment of UTI and the possible
harmful effect of UTI on several pregnancy outcomes as
suggested by previous studies. However, the adjusted
ORs did not show any significant results. Crude ORs
showed an increased risk for having a SGA-infant among
the women who had been exposed to cranberry, UTI
and no antibiotics. However, adjusted analyses and fur-
ther sub-analyses as previously described did not find
any association. This is in accordance with Schieve et al.,
who found a significant increased risk for having a SGA-
infant among women exposed to UTI during pregnancy,
which was non-significant after adjustment [12]. Never-
theless, cranberry should not be used to treat UTIs be-
cause there is no scientific evidence to support this use
[25]. Bacteriuria has been associated with adverse preg-
nancy outcomes such as low birth weight and preterm
delivery [11-14], and untreated ASB is seen to progress
to pyelonephritis in 20–40% of pregnant women [9,55].
Pyelonephritis is a serious medical complication of preg-
nancy and a common reason for hospitalization during
pregnancy [9,56]. However, antibiotic treatment of ASB
is seen to reduce the incidence of pyelonephritis and the
incidence of low birth weight infants [11,17], implying
the importance of proper treatment of this condition
during pregnancy.
This study has several strengths and limitations. The
main strength of the study is the large sample size of the
cohort. The risk of recall bias was reduced as a conse-
quence of the prospective nature of data collection in
the first two questionnaires completed by the women
during pregnancy. However, as the third questionnaire
was completed 6 months after giving birth, there might
be some recall bias. This could only occur among the 69
women who reported cranberry use between completionof the second questionnaire and delivery in the third
questionnaire. This represents 7.5% of the women who
used cranberry in pregnancy. Additionally, the vast var-
iety of information on socio-demographic data and
pregnancy-related variables, derived from both the de-
tailed MoBa-questionnaires and MBRN, enabled con-
trolling for important potentially confounding factors
while performing multivariate analyses on the associ-
ation between use of cranberry during pregnancy and
the selected adverse pregnancy outcomes including mal-
formations. MBRN has been shown to have satisfactory
accuracy, as reported by different validation studies
[57,58]. Still, it cannot be ruled out that there is a possi-
bility of under-reporting of minor malformations is likely
to occur, especially among early stillbirths.
A limitation of MoBa is the low response rate, which
may give rise to selection bias. Though minor differences
in prevalence estimates are seen between the partici-
pants in MoBa and the general population, risk estimates
have been shown to be valid for the MoBa data set [59].
Another limitation of the study is that MoBa is based
upon self-reporting. Therefore, information on use of
cranberry and the diagnosis UTI may not be complete
as the medical diagnosis of ASB or symptomatic bacteri-
uria have not been confirmed. Additionally, the doses
and administration forms were not available. The total
daily dose, duration of treatment, frequency of treatment
and adjunct herbals ingested along with cranberry are
therefore uncertain. Furthermore, we did not include
dietary intake of cranberry products (i.e. juice, berries) in
our study, although this could have been a potential im-
portant confounder to adjust for. Lastly, though it is the
largest study identified to investigate the safety of cran-
berry, there were few cases with malformations.
Conclusions
In conclusion, because of the widespread use of cranberry
during pregnancy, the results of this study are of clinical
relevance. Even though there is no clear scientific evidence
to support the use of cranberry either for the prevention
of, or in the treatment of UTIs, pregnant women will
probably continue to use this herb because of the long-
term history of its use. The findings of this study, revealing
no increased risk of malformations or any of the following
pregnancy outcomes: stillbirth/neonatal death, preterm
delivery, low birth weight, small for gestational age, low
Apgar score and neonatal infections, are therefore reassur-
ing. However, maternal vaginal bleeding should be investi-
gated further before any firm conclusions can be drawn.
Although pregnant women should be strongly encouraged
to use antibiotics against any detected urinary tract infec-
tion, cranberry does not appear to be a harmful adjunctive
self-therapy with regards to our data and the pregnancy
outcomes studied.
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